Sales of Regeneron Pharmaceuticals' Eylea have declined over the past few quarters due to competition. However, the company launched a new formulation of the medicine that just earned another label ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It took three years after buying ...

A medical device company from Ireland, a biotech startup developing cancer therapeutics from Pennsylvania and a venture studio focused on women’s health from Massachusetts are among eight recipients ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity ...

On Monday, Anthropic announced Opus 4.5, the latest version of its flagship model. It’s the last of Anthropic’s 4.5 series of models to be released, following the launch of Sonnet 4.5 in September and ...

Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead Sciences for $14 million upfront, plus the chance to net up to $400 million in biobucks. Last year, ...